Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, et al. Cutaneous melanoma. Nat Rev Dis Primers. 2025;11:23.
Google Scholar
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175–80.
Google Scholar
Huang C, Lau TW-S, Smoller BR. Diagnosing cutaneous melanocytic tumors in the molecular era: updates and review of literature. Dermatopathology. 2024;11:26–51.
Google Scholar
Goyal A, Murkute SL, Bhowmik S, Prasad CP, Mohapatra P. Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies. Biochim Biophys Acta Rev Cancer. 2024;1879:189195.
Google Scholar
Ruan B, Wang C, Gao X, Zhang Z, Niu Z, Liang J, et al. ARHGAP36 imposes a bifurcate activation of adherens junction and actomyosin to promote entosis. Cell Death Differ. Nature Publishing Group; 2026. p. 1–18.
Liu Y-T, Chen L, Li S-J, Wang W-Y, Wang Y-Y, Yang Q-C, et al. Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells. Cell Death Differ. 2024;31:1452–66.
Google Scholar
Xu L, Liu Q, Liu H, Fan F, Li P, Yue S, et al. Disrupting CCDC137-mediated LZTS2 and β-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via β-catenin and AKT. Cell Death Differ. 2025;32:134–48.
Google Scholar
Raymond JH, Aktary Z, Pouteaux M, Petit V, Luciani F, Wehbe M, et al. Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin. Nature. 2025;643:801–9.
Google Scholar
Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, et al. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. PLoS ONE. 2014;9:e94748.
Google Scholar
Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA. 2009;106:1193–8.
Google Scholar
Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. beta-Catenin signaling controls metastasis in BRAF-activated PTEN-deficient melanomas. Cancer Cell. 2011;20:741–54.
Google Scholar
Gallagher SJ, Rambow F, Kumasaka M, Champeval D, Bellacosa A, Delmas V, et al. Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene. 2013;32:2230–8.
Google Scholar
Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol. 1999;154:325–9.
Google Scholar
Xu S, Yang Z, Zhang J, Jiang Y, Chen Y, Li H, et al. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. DNA Cell Biol. 2015;34:69–77.
Google Scholar
Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes & Development. 2007;21:2923–35.
Google Scholar
Campàs O, Noordstra I, Yap AS. Adherens junctions as molecular regulators of emergent tissue mechanics. Nat Rev Mol Cell Biol. 2024;25:252–69.
Google Scholar
Takahashi M, Fujita M, Furukawa Y, Hamamoto R, Shimokawa T, Miwa N, et al. Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. Cancer Res. 2002;62:5651–6.
Google Scholar
Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci. 2008;99:1139–46.
Google Scholar
Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA. 2001;98:14973–8.
Google Scholar
Goodall J, Carreira S, Denat L, Kobi D, Davidson I, Nuciforo P, et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 2008;68:7788–94.
Google Scholar
Hari L, Miescher I, Shakhova O, Suter U, Chin L, Taketo M, et al. Temporal control of neural crest lineage generation by Wnt/beta-catenin signaling. Development. 2012;139:2107–17.
Google Scholar
Schepsky A, Bruser K, Gunnarsson GJ, Goodall J, Hallsson JH, Goding CR, et al. The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol. 2006;26:8914–27.
Google Scholar
Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Udono T, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem. 2000;275:14013–6.
Google Scholar
Uka R, Britschgi C, Krättli A, Matter C, Mihic D, Okoniewski MJ, et al. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene. 2020;39:4132–54.
Google Scholar
Larue L. E-Cadherin, MITF, and Phenotypic Plasticity in Melanoma: a crossroads between cell adhesion, differentiation, and hormonal regulation. J Investig Dermatol. 2025;25:03623–1.
Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33:1295–318.
Google Scholar
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.
Hao HX, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485:195–200.
Google Scholar
Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2.a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22:1172–83.
Google Scholar
Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002;22:1184–93.
Google Scholar
Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA. 2001;98:14973–8.
Google Scholar
Shimomura Y, Agalliu D, Vonica A, Luria V, Wajid M, Baumer A, et al. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. Nature. 2010;464:1043–7.
Google Scholar
Rousset R, Mack JA, Wharton KAJ, Axelrod JD, Cadigan KM, Fish MP, et al. Naked cuticle targets dishevelled to antagonize Wnt signal transduction. Genes Dev. 2001;15:658–71.
Google Scholar
Giráldez AJ, Copley RR, Cohen SM. HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient. Dev Cell. 2002;2:667–76.
Google Scholar
Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, et al. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-catenin pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog. 2009;48:942–52.
Google Scholar
Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422–6.
Google Scholar
Fujimura N, Vacik T, Machon O, Vlcek C, Scalabrin S, Speth M, et al. Wnt-mediated down-regulation of Sp1 target genes by a transcriptional repressor Sp5. J Biol Chem. 2007;282:1225–37.
Google Scholar
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739–40.
Google Scholar
Watanabe K, Biesinger J, Salmans ML, Roberts BS, Arthur WT, Cleary M, et al. Integrative ChIP-seq/microarray analysis identifies a CTNNB1 target signature enriched in intestinal stem cells and colon cancer. PLoS ONE. 2014;9:e92317.
Google Scholar
Wang R, Hou Z, Gao X, Wu B, Hu H, Wu H. The role of MICAL2 in cancer progression: mechanisms, challenges, and therapeutic potential. Hum Cell. 2025;38:89.
Google Scholar
Frémont S, Romet-Lemonne G, Houdusse A, Echard A. Emerging roles of MICAL family proteins – from actin oxidation to membrane trafficking during cytokinesis. J Cell Sci. 2017;130:1509–17.
Google Scholar
Nachef M, Ali AK, Almutairi SM, Lee S-H. Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment. Front Immunol. 2021;12:624324.
Google Scholar
Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, Saxonov S, et al. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 2010;6:e1000993.
Google Scholar
Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185–92.
Google Scholar
Rambow F, Job B, Petit V, Gesbert F, Delmas V, Seberg H, et al. New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis. Cell Rep. 2015;13:840–53.
Google Scholar
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual disease-directed therapy in melanoma. Cell. 2018;174:843–55.e19.
Google Scholar
Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013;73:4383–94.
Google Scholar
Tröster BC, Kappelmann-Fenzl M, Bosserhoff AK, Rachinger N. Emerging role of ARHGAP29 in melanoma cell phenotype switching. Mol Oncol. 2025;20:348–68.
Koren T, Zagairy F, Tatour Y, Belhanes-Peled H, Khayat M, Krausz J, et al. Potential digenic contribution to guttate leukoderma as the predominant feature of epidermolysis bullosa simplex. Exp Dermatol. 2022;31:1927–31.
Google Scholar
Rajan S, Terman JR, Reisler E. MICAL-mediated oxidation of actin and its effects on cytoskeletal and cellular dynamics. Front Cell Dev Biol. 2023;11:1124202.
Google Scholar
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392:11–22.
Google Scholar
Barreno A, Orgaz JL. Cytoskeletal remodelling as an Achilles’ heel for therapy resistance in melanoma. Cells. 2022;11:518.
Google Scholar
Garg B, Khan S, Courelli AS, Panneerpandian P, Sheik Pran Babu D, Mose ES, et al. MICAL2 promotes pancreatic cancer growth and metastasis. Cancer Res. 2025;85:1049–63.
Google Scholar
Wang Q, Qi C, Min P, Wang Y, Ye F, Xia T, et al. MICAL2 contributes to gastric cancer cell migration via Cdc42-dependent activation of E-cadherin/β-catenin signaling pathway. Cell Commun Signal. 2022;20:136.
Google Scholar
Lundquist MR, Storaska AJ, Liu T-C, Larsen SD, Evans T, Neubig RR, et al. Redox modification of nuclear actin by MICAL-2 regulates SRF signaling. Cell. 2014;156:563–76.
Google Scholar
Foda BM, Baker AE, Joachimiak Ł, Mazur M, Neubig RR. Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: implications for the involvement of pirin. Front Pharmacol. 2025;16:1505000.
Google Scholar
Lisabeth EM, Kahl D, Gopallawa I, Haynes SE, Misek SA, Campbell PL, et al. Identification of pirin as a molecular target of the CCG-1423/CCG-203971 series of antifibrotic and antimetastatic compounds. ACS Pharmacol Transl Sci. 2019;2:92–100.
Google Scholar
Cancer Genome Atlas NetworkGenomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.
Google Scholar
Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
Google Scholar
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
Google Scholar
Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.
Google Scholar
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
Google Scholar
Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016.
Estarás C, Benner C, Jones KA. SMADs and YAP compete to control elongation of β-catenin:LEF-1-recruited RNAPII during hESC differentiation. Mol Cell. 2015;58:780–93.
Google Scholar
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
Google Scholar
Zhang X, Lu M, Zhu J, Zhang C, Wang M. Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer. Exp Ther Med. 2023;25:29.
Google Scholar
Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 2005;65:4005–11.
Google Scholar
Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014;4:1418–29.
Google Scholar
Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic BRAF induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294–303.
Google Scholar
Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis. 2006;44:34–43.
Google Scholar
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
Google Scholar
Ho Y-J, Anaparthy N, Molik D, Mathew G, Aicher T, Patel A, et al. Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations. Genome Res. 2018;28:1353–63.
Google Scholar
Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495–502.
Google Scholar
Borcherding N, Vishwakarma A, Voigt AP, Bellizzi A, Kaplan J, Nepple K, et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun Biol. 2021;4:122.
Google Scholar
Flower CT, Liu C, Chuang H-Y, Ye X, Cheng H, Heath JR, et al. Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition. Cell Syst. 2025;16:101239.
Google Scholar
